Pharma Globenewswire

Eli Lilly’s Sofetabart Mipitecan Receives FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer

21 January 2026

Eli Lilly and Company announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to sofetabart mipitecan (LY4170156) for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (PROC) who have previously received

Protein Expression Competitive Landscape

Market Insights·News

Global Protein Expression Market Size is Poised to Hit USD 6,491.18 Million by 2032

21 January 2026

According to a recent analysis by DelveInsight, the global protein expression market is poised for strong growth, projected to reach USD 6,491.18 million by 2032, expanding at a CAGR of 7.67% during the forecast period from 2025 to 2032. This growth trajectory

Clinical Trials

Corvus Pharmaceuticals Reports Robust Phase 1 Cohort 4 Data for Soquelitinib in Atopic Dermatitis

21 January 2026

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company pioneering interleukin-2-inducible T-cell kinase (ITK) inhibition as a novel immunotherapy platform, announced today positive results from Cohort 4 of its randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate

Drug Launches & Approvals

FDA Approves Agios’ AQVESME (mitapivat) as First Oral Therapy for Thalassemia: A Watershed Moment for Anemia Management

21 January 2026

The Food and Drug Administration (FDA) has granted approval to AQVESME (mitapivat), marking a historic milestone in the thalassemia treatment. As the first oral therapy indicated for adults with both non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia, this approval represents a

Market Insights·News·Reports

Chronic Refractory Cough Market Hits $8.5B in 2024!

21 January 2026

The chronic refractory cough (CRC) market is projected to witness substantial growth through 2034, driven by an expanding diagnosed patient population, increasing recognition of chronic cough as a distinct clinical condition, and the shortcomings of currently used off-label therapies. Chronic Refractory Cough

Chemotherapy-Induced Peripheral Neuropathy Market

Uncategorised

CIPN Market Size was around USD 1,500 million in 2023

21 January 2026

The chemotherapy-induced peripheral neuropathy (CIPN) treatment market is emerging as a high-growth, high-value opportunity, fueled by a profound lack of approved therapies and a substantial unmet clinical need. As the global use of chemotherapy particularly neurotoxic agents continues to rise, the number

Market Insights·News·Reports

Geographic Atrophy Market Poised for Robust Growth

21 January 2026

The global Geographic Atrophy Market is expected to witness substantial growth over the forecast period from 2025 to 2034, fueled by a rising elderly population, increasing disease prevalence, growing demand for disease-modifying treatments, and the advancement of novel therapeutic approaches—particularly complement inhibitor

Market Insights

Sickle Cell Disease Market Set for Robust Expansion at a CAGR of 22.1% (2025–2034) Across 6MM, Driven by Rising Prevalence and Breakthrough Gene Therapies

20 January 2026

The Sickle Cell Disease (SCD) market is projected to experience remarkable growth through 2034, supported by increasing disease prevalence, improving diagnostic awareness, and rapid advancements in disease-modifying and gene-based therapies. According to DelveInsight, the market is expected to expand at a CAGR

Clinical Trials

Lantern Pharma’s LP-284 Achieves Third FDA Orphan Drug Designation for Soft Tissue Sarcomas

20 January 2026

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage artificial intelligence-driven biopharmaceutical company pioneering synthetic lethal approaches to oncology, announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. This marks

Latest

Eli Lilly’s Sofetabart Mipitecan Receives FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer

Global Protein Expression Market Size is Poised to Hit USD 6,491.18 Million by 2032

Corvus Pharmaceuticals Reports Robust Phase 1 Cohort 4 Data for Soquelitinib in Atopic Dermatitis

FDA Approves Agios’ AQVESME (mitapivat) as First Oral Therapy for Thalassemia: A Watershed Moment for Anemia Management

Chronic Refractory Cough Market Hits $8.5B in 2024!

CIPN Market Size was around USD 1,500 million in 2023

Geographic Atrophy Market Poised for Robust Growth

Sickle Cell Disease Market Set for Robust Expansion at a CAGR of 22.1% (2025–2034) Across 6MM, Driven by Rising Prevalence and Breakthrough Gene Therapies

Lantern Pharma’s LP-284 Achieves Third FDA Orphan Drug Designation for Soft Tissue Sarcomas

Recent Posts

Recent Comments

Hi There!

Banner

Latest Interviews

Newsletter

Authors